Dr Reddy's Laboratories announced on 21 October 2026 that the DCGI has approved Zytorvi (toripalimab) with cisplatin and paclitaxel as first-line treatment for adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC); the approval letter is dated 24 September 2026.
It is the drug's second indication in India, after nasopharyngeal carcinoma (launched November 2024).
In the Phase 3 JUPITER-06 trial, adding toripalimab to chemotherapy cut the risk of progression or death by 42% and raised median overall survival to 17.7 months from 12.9.
Patients need not be selected by PD-L1 expression; ESCC makes up about 80% of esophageal cancer cases in India.
PD-1 on T cells acts as a brake; tumours exploit it by displaying PD-L1. Blocking PD-1 releases the brake so T cells attack cancer cells. The discovery won James Allison and Tasuku Honjo the 2018 Nobel Prize in Physiology or Medicine.
Simple Analogy: Cutting the cord a burglar uses to switch off the alarm.
National regulator for drugs and medical devices under the Ministry of Health and Family Welfare; approves new drugs and clinical trials
Parent law under which the DCGI/CDSCO regulates drugs
Rules under the 1940 Act governing approval of new drugs such as this one
GS Paper III > Science and Technology — biotechnology, health
General Awareness > Science — diseases and treatment
Programmed cell death protein 1, an immune checkpoint receptor on T cells
A tumour that cannot be removed by surgery
The first therapy given for a disease in a given setting